Artículos por temáticas

A review of the application of exercise intervention on improving cognition in patients with Alzheimer's disease: mechanisms and clinical studies

Wang M, Hua Y, Bai Y.

Rev Neurosci. 2024 Jul 22;36(1):1-25. doi: 10.1515/revneuro-2024-0046. Print 2025 Jan 29.

Indole-based COX-2 inhibitors: A decade of advances in inflammation, cancer, and Alzheimer's therapy

Shah M, Parmar R, Patel K, Nagani A.

Bioorg Chem. 2024 Dec;153:107931. doi: 10.1016/j.bioorg.2024.107931. Epub 2024 Oct 29.

Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer's, Parkinson's, and ALS

Toader C, Tataru CP, Munteanu O, Serban M, Covache-Busuioc RA, Ciurea AV, Enyedi M.

Int J Mol Sci. 2024 Nov 24;25(23):12613. doi: 10.3390/ijms252312613.

Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy

Sai Varshini M, Aishwarya Reddy R, Thaggikuppe Krishnamurthy P.

J Drug Target. 2024 Sep;32(8):909-917. doi: 10.1080/1061186X.2024.2365263. Epub 2024 Jun 11.

Understanding Glycogen Synthase Kinase-3: A Novel Avenue for Alzheimer's Disease

Sequeira RC, Godad A.

Mol Neurobiol. 2024 Jul;61(7):4203-4221. doi: 10.1007/s12035-023-03839-1. Epub 2023 Dec 8.

Recent Advances in Medicinal Chemistry of Memantine Against Alzheimer's Disease

Singh YP, Kumar H.

Chem Biol Drug Des. 2024 Oct;104(4):e14638. doi: 10.1111/cbdd.14638.

Unlocking choline's potential in Alzheimer's disease: A narrative review exploring the neuroprotective and neurotrophic role of phosphatidylcholine and assessing its impact on memory and learning

Conway T, Seidler K, Barrow M.

Clin Nutr ESPEN. 2024 Dec;64:177-195. doi: 10.1016/j.clnesp.2024.09.024. Epub 2024 Sep 30.

Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson's and Alzheimer's disease

McDowall S, Bagda V, Hodgetts S, Mastaglia F, Li D.

Transl Neurodegener. 2024 Dec 3;13(1):59. doi: 10.1186/s40035-024-00450-9.

Berberine: A Multi-Target Natural PCSK9 Inhibitor with the Potential to Treat Diabetes, Alzheimer's, Cancer and Cardiovascular Disease

Coppinger C, Pomales B, Movahed MR, Marefat M, Hashemzadeh M.

Curr Rev Clin Exp Pharmacol. 2024;19(4):312-326. doi: 10.2174/0127724328250471231222094648.

Natural compounds from herbs and nutraceuticals as glycogen synthase kinase-3β inhibitors in Alzheimer's disease treatment

Zhao Z, Yuan Y, Li S, Wang X, Yang X.

CNS Neurosci Ther. 2024 Aug;30(8):e14885. doi: 10.1111/cns.14885.

The Use of Neurotrophic Factors as a Promising Strategy for the Treatment of Neurodegenerative Diseases (Review)

Fursa GA, Andretsova SS, Shishkina VS, Voronova AD, Karsuntseva EK, Chadin AV, Reshetov IV, Stepanova OV, Chekhonin VP.

Bull Exp Biol Med. 2024 Aug;177(4):517-527. doi: 10.1007/s10517-024-06218-5. Epub 2024 Sep 12.

Polyphenols and Their Biogenic Nano-Formulations Targeting BACE1 as Anti-Amyloid Therapies; Meeting the Challenges of Bioavailability, Safety, and Specificity for the Treatment of Alzheimer's Disease

Elawad MA, Ayaz M, Mosa OF, Usman A, Hamdoon AAE, Almawash S, Salim LHM, Ahmed A, Elkhalifa MEM.

Mol Nutr Food Res. 2024 Dec;68(24):e2400525. doi: 10.1002/mnfr.202400525. Epub 2024 Dec 4.

Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease

Wang HJ, Chinna-Meyyappan A, Feldman OJ, Lanctôt KL.

Expert Opin Emerg Drugs. 2024 Sep;29(3):289-303. doi: 10.1080/14728214.2024.2363215. Epub 2024 Jun 11.

What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease

Jin M, Noble JM.

eNeuro. 2024 Sep 27;11(9):ENEURO.0088-24.2024. doi: 10.1523/ENEURO.0088-24.2024. Print 2024 Sep.

Hypertension & dementia: Pathophysiology & potential utility of antihypertensives in reducing disease burden

Lyon M, Fullerton JL, Kennedy S, Work LM.

Pharmacol Ther. 2024 Jan;253:108575. doi: 10.1016/j.pharmthera.2023.108575. Epub 2023 Dec 3.